Literature DB >> 29458555

Does Toxoplasma gondii infection impact liver transplantation outcomes? A systematic review.

Maria de la Luz Galván-Ramírez1, Laura V Sánchez-Orozco2, Adrián Fernando Gutiérrez-Maldonado1, Laura Roció Rodriguez Pérez1.   

Abstract

PURPOSE: Approximately one-third of the world's population has Toxoplasma gondii infection, and one of the main routes of transmission is organ transplantation. The aim of this study was to evaluate the impact of Toxoplasma infection on liver transplantation patients.
METHODOLOGY: We searched PubMed, Lilacs, Medline, Science direct, Scielo, Ebsco, Springer, Wiley, Ovid and Google Scholar for reports published up to June 2017, and a systematic review was performed.
RESULTS: Twenty cases were analysed before and after liver transplantation. Primary and reactivated infections were investigated. Before transplantation, positive IgG antibodies were the predominant serological markers in donors and recipients: 40 % (D+/R-), 20 % (D+/R+) and 20 % (D-/R+). IgM was present in only 5 % of the donors (D+/R-). In four cases, the serological markers were not specified or were negative (D?/R? or D?/R-). After transplantation, IgM anti-Toxoplasma antibodies were found in 30 % of the recipients, and in 67 % of the seronegative recipients the presence of Toxoplasma DNA or tachyzoites was reported, suggesting a primary infection. Clinical symptoms were meningitis, massive cerebral oedema, encephalitis and seizures. Treatment was administered in 70 % of the patients, and 40 % died after presenting symptoms associated with Toxoplasma infection.
CONCLUSIONS: Although we review Toxoplasma infection and liver transplantation cases, problems associated with the parasite may be greater than identified. Hence, follow-up studies on Toxoplasma infection in liver transplantation patients are recommended.

Entities:  

Keywords:  Toxoplasma infection; diagnostic; liver transplant; systematic review; treatment

Mesh:

Substances:

Year:  2018        PMID: 29458555     DOI: 10.1099/jmm.0.000694

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

Review 1.  The molecular biology and immune control of chronic Toxoplasma gondii infection.

Authors:  Xiao-Yu Zhao; Sarah E Ewald
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

2.  Tamoxifen Increased Parasite Burden and Induced a Series of Histopathological and Immunohistochemical Changes During Chronic Toxoplasmosis in Experimentally Infected Mice.

Authors:  Ashraf Mohamed Barakat; Hassan Ali Mohamed El Fadaly; Rabab Fawzy Selem; Abd El-Nasser A Madboli; Khaled A Abd El-Razik; Ehssan Ahmed Hassan; Ali H Alghamdi; Ehab Kotb Elmahallawy
Journal:  Front Microbiol       Date:  2022-05-30       Impact factor: 6.064

Review 3.  Catastrophic consequences: can the feline parasite Toxoplasma gondii prompt the purrfect neuroinflammatory storm following traumatic brain injury?

Authors:  Tamara L Baker; Mujun Sun; Bridgette D Semple; Shiraz Tyebji; Christopher J Tonkin; Richelle Mychasiuk; Sandy R Shultz
Journal:  J Neuroinflammation       Date:  2020-07-25       Impact factor: 8.322

Review 4.  Disease Tolerance in Toxoplasma Infection.

Authors:  Stephanie J Melchor; Sarah E Ewald
Journal:  Front Cell Infect Microbiol       Date:  2019-06-06       Impact factor: 5.293

Review 5.  Anti-Toxoplasma gondii IgM Long Persistence: What Are the Underlying Mechanisms?

Authors:  José Antonio Vargas-Villavicencio; Irma Cañedo-Solares; Dolores Correa
Journal:  Microorganisms       Date:  2022-08-17

6.  Toxoplasma gondii Monitoring in Liver Transplantation Patients: A Single Center Cross-Sectional Study in an Italian Hospital.

Authors:  Barbara Pinto; Federica Lotti; Stefania Petruccelli; Paola Carrai; Paolo De Simone; Fabrizio Bruschi
Journal:  Pathogens       Date:  2020-05-08

7.  Serological prevalence of toxoplasmosis in pregnant women in Luanda (Angola): Geospatial distribution and its association with socio-demographic and clinical-obstetric determinants.

Authors:  Amélia Nkutxi Vueba; Clarissa Perez Faria; Ricardo Almendra; Paula Santana; Maria do Céu Sousa
Journal:  PLoS One       Date:  2020-11-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.